Want to see HK:2563 full AI Analyst Report?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) AI Stock Analysis
Top Page
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
(HKEX:2563)
The score is held back primarily by weak financial performance—sharp revenue decline, persistent heavy losses, and ongoing cash burn—despite a low-debt balance sheet. Technicals provide some support due to a strong uptrend and positive MACD, but overbought readings increase near-term risk. Valuation remains constrained by negative earnings (negative P/E) and no dividend yield data.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 821.85M
- Dividend Yield
- ―
- Average Volume (3M)
- 27.95K
- Price to Earnings (P/E)
- -9.9
- Beta (1Y)
- 0.24
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 134
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in i...
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Financial Statement Overview
Summary
Overall financials are weak: revenue is highly volatile and fell sharply in 2025 (~-51% YoY), while the company remains deeply unprofitable with persistent large net losses and very negative margins. Cash flow is a major drag with recurring negative operating cash flow and free cash flow (continued cash burn). The main offsetting strength is a very low-debt balance sheet, which reduces near-term solvency risk but does not solve profitability and funding pressure.
Income Statement
18Very NegativeBalance Sheet
72PositiveCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 64.58M | 37.12M | 77.92M | 73.75M | 37.38M | 106.74M |
| Gross Profit | 59.71M | 33.65M | 66.75M | 51.83M | 27.20M | 100.48M |
| EBITDA | -105.53M | -139.77M | -173.84M | -198.08M | -170.77M | -430.65M |
| Net Income | -124.61M | -142.54M | -155.89M | -209.90M | -182.81M | -417.79M |
Balance Sheet | ||||||
| Total Assets | 855.87M | 861.37M | 971.51M | 854.83M | 1.06B | 1.45B |
| Cash, Cash Equivalents and Short-Term Investments | 516.22M | 508.15M | 609.16M | 637.54M | 830.57M | 988.06M |
| Total Debt | 1.61M | 2.20M | 1.26M | 995.01K | 2.17M | 1.72M |
| Total Liabilities | 116.80M | 120.36M | 130.31M | 54.44M | 66.53M | 30.34M |
| Stockholders Equity | 739.07M | 741.01M | 841.20M | 800.40M | 988.49M | 1.42B |
Cash Flow | ||||||
| Free Cash Flow | -67.06M | -174.59M | -163.18M | -197.69M | -127.69M | -134.93M |
| Operating Cash Flow | -63.63M | -168.56M | -119.77M | -166.88M | -90.47M | -118.32M |
| Investing Cash Flow | -14.74M | 99.59M | 56.88M | 145.30M | -167.18M | 192.93M |
| Financing Cash Flow | -1.52M | -1.39M | 221.38M | -1.25M | 4.02M | -1.21M |
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2563, the sentiment is Negative. The current price of 3.40 is below the 20-day moving average (MA) of 4.08, below the 50-day MA of 4.01, and below the 200-day MA of 3.80, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 25.16 is Positive, neither overbought nor oversold. The STOCH value of 15.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2563.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Peers Comparison
Overall Rating
HK:804973Outperform
HK:218659Neutral
HK:608658Neutral- HK:256351Neutral
HK:122846Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:8049 | 73Outperform | HKD 1.48B | 4.49 | 15.91% | ― | 0.20% | 24.13% |
| HK:2186 | 59Neutral | HKD 6.23B | 7.73 | 4.40% | ― | 2.84% | 71.92% |
| HK:6086 | 58Neutral | HKD 1.39B | 141.42 | 3.67% | ― | 38.59% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:2563 | 51Neutral | HKD 1.32B | -9.90 | -16.60% | ― | ― | ― |
| HK:1228 | 46Neutral | HKD 1.06B | -9.52 | 30.32% | ― | -8.00% | 51.26% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2563 | Beijing Biostar Pharmaceuticals Co., Ltd. Class H | 3.40 | 0.22 | 6.92% | |
| HK:2186 | Luye Pharma Group | 1.58 | -1.64 | -50.78% | |
| HK:8049 | Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H | 2.65 | 0.69 | 35.55% | |
| HK:1228 | CANbridge Pharmaceuticals Inc. | 1.77 | -0.21 | -10.61% | |
| HK:6086 | Fangzhou Inc. | 1.00 | -2.62 | -72.38% | |
| HK:2566 | Hangzhou Jiuyuan Gene Engineering Co Ltd Class H | 4.98 | -3.17 | -38.87% |
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Corporate Events
Beijing Biostar Advances Oral Utidelone to Phase III in HER2-Negative Breast Cancer
Beijing Biostar Pharmaceuticals has reached a key milestone in its oncology pipeline, with its oral Utidelone Capsule (UTD2) initiating first patient dosing in a Phase III trial for HER2-negative advanced breast cancer. The pivotal registration study...
Beijing Biostar Pharmaceuticals Doubles Revenue and Narrows Losses in First Half of 2026
Beijing Biostar Pharmaceuticals reported a sharp improvement in interim financial performance for the six months ended June 30, 2026, with revenue rising 147.8% year-on-year to RMB36.6 million and gross profit increasing at a similar pace. Despite th...
Beijing Biostar Pharmaceuticals Sets Board Meeting to Review Interim Results and Dividend
Beijing Biostar Pharmaceuticals has scheduled a board meeting for 26 August 2026 to review its consolidated interim results for the six months ended 30 June 2026 and to consider their publication. The meeting will also discuss whether to recommend an...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026